Compare Amgen, Inc. (AMGN) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs JD.Com Inc — how do they compare? Amgen, Inc. trades at $356.22 (market cap $196.12B), while JD.Com Inc trades at $29 (market cap $38.39B). The key difference: Amgen, Inc. is far larger — about 5.1× JD.Com Inc's market cap, and JD.Com Inc pays the higher dividend (3.55%). Which is the better fit depends on your goals.
| AMGN | JD | |
|---|---|---|
Market Cap | $196.12B | $38.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $36.17 |
52-Week Low | $271.18 | $25.19 |
Enterprise Value | $241.41B | $24.55B |
Dividend Yield | 2.77% | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
JD.com trades at $28.20, up 1.66% today, with a bullish technical signal from moving averages. The company reported revenue of $1.31 trillion in 2025, though net income fell to $19.63 billion, reducing the profit margin to 1.49%. Recent quarters show consistent earnings beats, and analyst sentiment is strongly positive with a consensus price target of $39.20. News highlights include a rally in Chinese tech stocks and ongoing legal investigations.
The outlook is supported by low valuation multiples and strong cash flow, but risks include regulatory scrutiny and margin pressure. Upside potential exists if earnings growth resumes, yet investor caution is warranted due to legal overhangs and competitive dynamics in e-commerce.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
